Atlas Trials

Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT

Clinical trial NCT06904183 · RECRUITING

Trial details

NCT number
NCT06904183
Sponsor
Second Affiliated Hospital of Guangzhou Medical University
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Hepatocellular Carcinoma Non-resectable
Start date
2025-04-01
Primary completion
2029-03-31
Enrollment
320

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.